News and Events
Arclin Acquires SURTECO Treating Facility for TFL Papers
19 July 2019
East Longmeadow, MA facility complements Arclin’s existing treating footprint
ATLANTA, GA, July 19, 2019 – Arclin, a chemistry-based manufacturer of engineered products for the building, design, transportation and other industries, announced today that it completed the acquisition of SURTECO’s North America decorative paper treating facility in East Longmeadow, MA. Terms of the agreement were not disclosed.
Acquisition of the facility expands Arclin’s footprint in North America, complementing the company’s existing treating operations in Tacoma, WA and Cobourg, ON. Arclin’s Chief Operating Officer Ralf Yobp commented, “This facility gives us greater flexibility to serve our North American customers by increasing geographic availability. The combined best practices of both companies will enhance Arclin’s ability to provide cost effective solutions for its customers in the face of increasing international competition.”
“The sale of the East Longmeadow treating facility to Arclin is a final step to return to our core competency of providing decorative surfaces and edgings to the North American market,” said SURTECO North America CEO and President Michael Phillips. “The partnership with Arclin will provide design and print as well as treating for complete surfacing solutions to existing and future customers,” he said.
Arclin provides treating for its own portfolio of designs for TFL and has significant custom-treat capacity for TFL customers. Combined with the company’s industrial surface treating assets, the company will now operate five treating facilities across North America, in addition to six chemical facilities.
Arclin is a leading provider of chemistry-based resin and surfacing systems for the building, design, energy, agriculture, transportation and other industries. Headquartered in Roswell, Georgia, Arclin has offices and manufacturing facilities throughout the U.S. and Canada and manufactures for customers worldwide. More information at www.arclin.com.